304 related articles for article (PubMed ID: 19633425)
41. Targeting of distinct signaling cascades and cancer-associated fibroblasts define the efficacy of Sorafenib against prostate cancer cells.
Kharaziha P; Rodriguez P; Li Q; Rundqvist H; Björklund AC; Augsten M; Ullén A; Egevad L; Wiklund P; Nilsson S; Kroemer G; Grander D; Panaretakis T
Cell Death Dis; 2012 Jan; 3(1):e262. PubMed ID: 22278289
[TBL] [Abstract][Full Text] [Related]
42. Sorafenib inhibits ERK1/2 and MCL-1(L) phosphorylation levels resulting in caspase-independent cell death in malignant pleural mesothelioma.
Katz SI; Zhou L; Chao G; Smith CD; Ferrara T; Wang W; Dicker DT; El-Deiry WS
Cancer Biol Ther; 2009 Dec; 8(24):2406-16. PubMed ID: 20038816
[TBL] [Abstract][Full Text] [Related]
43. Cyclic AMP/PKA-dependent paradoxical activation of Raf/MEK/ERK signaling in polycystin-2 defective mice treated with sorafenib.
Spirli C; Morell CM; Locatelli L; Okolicsanyi S; Ferrero C; Kim AK; Fabris L; Fiorotto R; Strazzabosco M
Hepatology; 2012 Dec; 56(6):2363-74. PubMed ID: 22653837
[TBL] [Abstract][Full Text] [Related]
44. Inhibition of tumor endothelial ERK activation, angiogenesis, and tumor growth by sorafenib (BAY43-9006).
Murphy DA; Makonnen S; Lassoued W; Feldman MD; Carter C; Lee WM
Am J Pathol; 2006 Nov; 169(5):1875-85. PubMed ID: 17071608
[TBL] [Abstract][Full Text] [Related]
45. Apoptosis induced by the kinase inhibitor BAY 43-9006 in human leukemia cells involves down-regulation of Mcl-1 through inhibition of translation.
Rahmani M; Davis EM; Bauer C; Dent P; Grant S
J Biol Chem; 2005 Oct; 280(42):35217-27. PubMed ID: 16109713
[TBL] [Abstract][Full Text] [Related]
46. PKI-587 and sorafenib targeting PI3K/AKT/mTOR and Ras/Raf/MAPK pathways synergistically inhibit HCC cell proliferation.
Gedaly R; Angulo P; Hundley J; Daily MF; Chen C; Evers BM
J Surg Res; 2012 Aug; 176(2):542-8. PubMed ID: 22261591
[TBL] [Abstract][Full Text] [Related]
47. Synergistic efficacy of sorafenib and genistein in growth inhibition by down regulating angiogenic and survival factors and increasing apoptosis through upregulation of p53 and p21 in malignant neuroblastoma cells having N-Myc amplification or non-amplification.
Roy Choudhury S; Karmakar S; Banik NL; Ray SK
Invest New Drugs; 2010 Dec; 28(6):812-24. PubMed ID: 19777160
[TBL] [Abstract][Full Text] [Related]
48. The multikinase inhibitor sorafenib potentiates TRAIL lethality in human leukemia cells in association with Mcl-1 and cFLIPL down-regulation.
Rosato RR; Almenara JA; Coe S; Grant S
Cancer Res; 2007 Oct; 67(19):9490-500. PubMed ID: 17909059
[TBL] [Abstract][Full Text] [Related]
49. Mcl-1 as a buffer for proapoptotic Bcl-2 family members during TRAIL-induced apoptosis: a mechanistic basis for sorafenib (Bay 43-9006)-induced TRAIL sensitization.
Meng XW; Lee SH; Dai H; Loegering D; Yu C; Flatten K; Schneider P; Dai NT; Kumar SK; Smith BD; Karp JE; Adjei AA; Kaufmann SH
J Biol Chem; 2007 Oct; 282(41):29831-46. PubMed ID: 17698840
[TBL] [Abstract][Full Text] [Related]
50. Synergistic inhibition of HCC and liver cancer stem cell proliferation by targeting RAS/RAF/MAPK and WNT/β-catenin pathways.
Galuppo R; Maynard E; Shah M; Daily MF; Chen C; Spear BT; Gedaly R
Anticancer Res; 2014 Apr; 34(4):1709-13. PubMed ID: 24692700
[TBL] [Abstract][Full Text] [Related]
51. Sorafenib sensitizes (-)-gossypol-induced growth suppression in androgen-independent prostate cancer cells via Mcl-1 inhibition and Bak activation.
Lian J; Ni Z; Dai X; Su C; Smith AR; Xu L; He F
Mol Cancer Ther; 2012 Feb; 11(2):416-26. PubMed ID: 22188816
[TBL] [Abstract][Full Text] [Related]
52. Sorafenib inhibits cAMP-dependent ERK activation, cell proliferation, and in vitro cyst growth of human ADPKD cyst epithelial cells.
Yamaguchi T; Reif GA; Calvet JP; Wallace DP
Am J Physiol Renal Physiol; 2010 Nov; 299(5):F944-51. PubMed ID: 20810616
[TBL] [Abstract][Full Text] [Related]
53. The dual PI3K/mTOR inhibitor PI-103 promotes immunosuppression, in vivo tumor growth and increases survival of sorafenib-treated melanoma cells.
López-Fauqued M; Gil R; Grueso J; Hernandez-Losa J; Pujol A; Moliné T; Recio JA
Int J Cancer; 2010 Apr; 126(7):1549-61. PubMed ID: 19810100
[TBL] [Abstract][Full Text] [Related]
54. Proliferation and survival molecules implicated in the inhibition of BRAF pathway in thyroid cancer cells harbouring different genetic mutations.
Preto A; Gonçalves J; Rebocho AP; Figueiredo J; Meireles AM; Rocha AS; Vasconcelos HM; Seca H; Seruca R; Soares P; Sobrinho-Simões M
BMC Cancer; 2009 Oct; 9():387. PubMed ID: 19878585
[TBL] [Abstract][Full Text] [Related]
55. Nelfinavir induces mitochondria protection by ERK1/2-mediated mcl-1 stabilization that can be overcome by sorafenib.
Brüning A; Burger P; Vogel M; Gingelmaier A; Friese K; Burges A
Invest New Drugs; 2010 Oct; 28(5):535-42. PubMed ID: 19554262
[TBL] [Abstract][Full Text] [Related]
56. The Bcl-xL inhibitor, ABT-737, efficiently induces apoptosis and suppresses growth of hepatoma cells in combination with sorafenib.
Hikita H; Takehara T; Shimizu S; Kodama T; Shigekawa M; Iwase K; Hosui A; Miyagi T; Tatsumi T; Ishida H; Li W; Kanto T; Hiramatsu N; Hayashi N
Hepatology; 2010 Oct; 52(4):1310-21. PubMed ID: 20799354
[TBL] [Abstract][Full Text] [Related]
57. NSK-01105 inhibits proliferation and induces apoptosis of prostate cancer cells by blocking the Raf/MEK/ERK and PI3K/Akt/mTOR signal pathways.
Yu P; Ye L; Wang H; Du G; Zhang J; Zhang J; Tian J
Tumour Biol; 2015 Mar; 36(3):2143-53. PubMed ID: 25398692
[TBL] [Abstract][Full Text] [Related]
58. Mitochondrial localization and regulation of BRAFV600E in thyroid cancer: a clinically used RAF inhibitor is unable to block the mitochondrial activities of BRAFV600E.
Lee MH; Lee SE; Kim DW; Ryu MJ; Kim SJ; Kim SJ; Kim YK; Park JH; Kweon GR; Kim JM; Lee JU; De Falco V; Jo YS; Shong M
J Clin Endocrinol Metab; 2011 Jan; 96(1):E19-30. PubMed ID: 20926530
[TBL] [Abstract][Full Text] [Related]
59. Phosphorylated ERK is a potential predictor of sensitivity to sorafenib when treating hepatocellular carcinoma: evidence from an in vitro study.
Zhang Z; Zhou X; Shen H; Wang D; Wang Y
BMC Med; 2009 Aug; 7():41. PubMed ID: 19698189
[TBL] [Abstract][Full Text] [Related]
60. Coadministration of sorafenib with rottlerin potently inhibits cell proliferation and migration in human malignant glioma cells.
Jane EP; Premkumar DR; Pollack IF
J Pharmacol Exp Ther; 2006 Dec; 319(3):1070-80. PubMed ID: 16959960
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
